2Xideas AG Sells 27,564 Shares of DexCom, Inc. $DXCM

2Xideas AG trimmed its position in DexCom, Inc. (NASDAQ:DXCM) by 16.1% during the 2nd quarter, HoldingsChannel reports. The firm owned 144,099 shares of the medical device company’s stock after selling 27,564 shares during the quarter. DexCom accounts for about 2.2% of 2Xideas AG’s investment portfolio, making the stock its 11th largest holding. 2Xideas AG’s holdings in DexCom were worth $12,578,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in DXCM. Horizon Investments LLC grew its holdings in DexCom by 2.2% during the 1st quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company’s stock valued at $383,000 after buying an additional 123 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of DexCom by 3.2% during the 1st quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company’s stock valued at $411,000 after acquiring an additional 187 shares during the last quarter. Integrated Wealth Concepts LLC grew its holdings in shares of DexCom by 6.3% in the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares in the last quarter. Trivium Point Advisory LLC raised its stake in DexCom by 6.1% during the first quarter. Trivium Point Advisory LLC now owns 3,455 shares of the medical device company’s stock valued at $236,000 after purchasing an additional 200 shares in the last quarter. Finally, STF Management LP lifted its position in DexCom by 5.5% during the second quarter. STF Management LP now owns 4,041 shares of the medical device company’s stock valued at $353,000 after purchasing an additional 211 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Trading Up 0.2%

Shares of NASDAQ DXCM opened at $65.62 on Tuesday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. The business’s 50 day moving average price is $63.95 and its 200-day moving average price is $74.87. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $93.25. The company has a market cap of $25.59 billion, a price-to-earnings ratio of 36.46, a PEG ratio of 1.40 and a beta of 1.51.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The company had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. DexCom had a return on equity of 30.65% and a net margin of 15.96%.DexCom’s revenue was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.45 EPS. On average, sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the completion of the sale, the director directly owned 27,031 shares of the company’s stock, valued at $1,569,690.17. The trade was a 3.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard Alexander Collins sold 2,906 shares of the company’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $59.05, for a total transaction of $171,599.30. Following the completion of the transaction, the director owned 35,088 shares in the company, valued at $2,071,946.40. This represents a 7.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 7,866 shares of company stock valued at $448,177. 0.32% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on DXCM shares. Morgan Stanley upgraded shares of DexCom from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $63.00 to $75.00 in a report on Tuesday, December 2nd. Robert W. Baird set a $82.00 price target on DexCom in a research report on Friday, October 31st. UBS Group reduced their price objective on DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, November 3rd. The Goldman Sachs Group decreased their price objective on DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Finally, Evercore ISI began coverage on DexCom in a report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $87.27.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.